Inhibrx Biosciences (INBX) Competitors $21.14 -0.21 (-0.96%) As of 11:22 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INBX vs. HROW, WVE, CDTX, CVAC, AUPH, PRAX, CALT, PAHC, SRPT, and DYNShould you be buying Inhibrx Biosciences stock or one of its competitors? The main competitors of Inhibrx Biosciences include Harrow (HROW), WAVE Life Sciences (WVE), Cidara Therapeutics (CDTX), CureVac (CVAC), Aurinia Pharmaceuticals (AUPH), Praxis Precision Medicines (PRAX), Calliditas Therapeutics AB (publ) (CALT), Phibro Animal Health (PAHC), Sarepta Therapeutics (SRPT), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry. Inhibrx Biosciences vs. Its Competitors Harrow WAVE Life Sciences Cidara Therapeutics CureVac Aurinia Pharmaceuticals Praxis Precision Medicines Calliditas Therapeutics AB (publ) Phibro Animal Health Sarepta Therapeutics Dyne Therapeutics Inhibrx Biosciences (NASDAQ:INBX) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends. Do analysts rate INBX or HROW? Harrow has a consensus target price of $63.83, suggesting a potential upside of 93.20%. Given Harrow's stronger consensus rating and higher probable upside, analysts clearly believe Harrow is more favorable than Inhibrx Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibrx Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Harrow 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, INBX or HROW? Inhibrx Biosciences has higher earnings, but lower revenue than Harrow. Harrow is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibrx Biosciences$200K1,530.17$1.69B$116.750.18Harrow$199.61M6.07-$17.48M-$0.56-59.00 Does the media refer more to INBX or HROW? In the previous week, Harrow had 6 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 7 mentions for Harrow and 1 mentions for Inhibrx Biosciences. Harrow's average media sentiment score of 0.17 beat Inhibrx Biosciences' score of 0.00 indicating that Harrow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harrow 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Is INBX or HROW more profitable? Inhibrx Biosciences has a net margin of 0.00% compared to Harrow's net margin of -10.19%. Harrow's return on equity of -25.01% beat Inhibrx Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Inhibrx BiosciencesN/A -85.12% -58.90% Harrow -10.19%-25.01%-4.27% Which has more volatility and risk, INBX or HROW? Inhibrx Biosciences has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500. Comparatively, Harrow has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Do insiders and institutionals hold more shares of INBX or HROW? 82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 17.1% of Inhibrx Biosciences shares are owned by insiders. Comparatively, 15.2% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryHarrow beats Inhibrx Biosciences on 9 of the 16 factors compared between the two stocks. Get Inhibrx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INBX vs. The Competition Export to ExcelMetricInhibrx BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$304.66M$2.98B$5.44B$9.65BDividend YieldN/A2.46%3.99%4.14%P/E Ratio0.1818.0530.0425.06Price / Sales1,530.17175.18373.4277.08Price / Cash0.1841.8335.9458.58Price / Book2.297.218.125.67Net Income$1.69B-$54.43M$3.25B$265.39M7 Day Performance-2.15%0.07%0.96%2.54%1 Month Performance5.99%5.29%2.69%1.89%1 Year Performance84.75%9.94%28.08%24.09% Inhibrx Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INBXInhibrx Biosciences1.3565 of 5 stars$21.14-1.0%N/A+86.2%$304.66M$200K0.18166Upcoming EarningsGap UpHROWHarrow2.3173 of 5 stars$34.86-3.7%$63.83+83.1%+51.1%$1.33B$212.86M-62.25180Upcoming EarningsWVEWAVE Life Sciences4.7011 of 5 stars$8.18-2.6%$20.43+149.7%+36.0%$1.31B$108.30M-9.74240CDTXCidara Therapeutics3.3794 of 5 stars$62.68+1.3%$57.29-8.6%+456.1%$1.25B$1.27M-2.1390News CoverageEarnings ReportAnalyst ForecastGap DownCVACCureVac4.4619 of 5 stars$5.42-0.7%$6.83+26.1%+64.5%$1.22B$579.18M5.89880News CoverageUpcoming EarningsAUPHAurinia Pharmaceuticals2.1475 of 5 stars$8.89-0.4%$11.50+29.4%+114.8%$1.21B$235.13M31.75300Insider TradePRAXPraxis Precision Medicines1.6654 of 5 stars$55.65-6.0%$94.11+69.1%-9.1%$1.21B$8.12M-5.19110Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180PAHCPhibro Animal Health4.0935 of 5 stars$28.92-0.9%$24.40-15.6%+60.8%$1.18B$1.02B37.081,940Positive NewsAnalyst RevisionSRPTSarepta Therapeutics4.6213 of 5 stars$13.86+16.2%$51.42+271.0%-87.2%$1.17B$1.90B-5.151,372Trending NewsEarnings ReportAnalyst ForecastDYNDyne Therapeutics3.3794 of 5 stars$9.31-6.4%$40.63+336.4%-73.5%$1.13BN/A-2.59100Upcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies Harrow Alternatives WAVE Life Sciences Alternatives Cidara Therapeutics Alternatives CureVac Alternatives Aurinia Pharmaceuticals Alternatives Praxis Precision Medicines Alternatives Calliditas Therapeutics AB (publ) Alternatives Phibro Animal Health Alternatives Sarepta Therapeutics Alternatives Dyne Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INBX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
